Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024

This Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Oncolytic Virus Cancer Therapy Understanding

Oncolytic Virus Cancer Therapy: Overview

Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oncolytic Virus Cancer Therapy pipeline landscape is provided which includes the disease overview and Oncolytic Virus Cancer Therapy treatment guidelines. The assessment part of the report embraces, in depth Oncolytic Virus Cancer Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncolytic Virus Cancer Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches to treat/improve Oncolytic Virus Cancer Therapy.
• In February 2022, Synthetic Biologics announced that VCN Biosciences, VCN-01 received Orphan Drug Designation for retinoblastoma from the US Food & Drug Administration (FDA).
• In March 2022, Synthetic Biologics announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.
• In September 2021, CG Oncology announced a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the treatment of metastatic urothelial cancer in a Phase I/II clinical study.
• In March 2021, Orgenesis Inc. announced that it has entered the planned second phase of a collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The collaboration is focused on an exclusive license agreement to further develop and commercialize the hospital’s proprietary Celyvir therapy for the treatment of solid tumors.

Oncolytic Virus Cancer Therapy Drugs
Olvi-Vec: Genelux CorporationOlvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
CAN-2409: Candel TherapeuticsCAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.

CG0070: CG OncologyCG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.

Pelareorep: Oncolytics BiotechPelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning cold tumors hot -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.

ParvOryx: Oryx GmbHParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.

SND005: Jiangsu Sinorda BiomedicineSND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.

VCN-01: VCN BiosciencesVCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.

Oncolytic Virus Cancer Therapy: Therapeutic Assessment

This segment of the report provides insights about the Oncolytic Virus Cancer Therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Oncolytic Virus Cancer Therapy

There are approx. 120+ key companies which are developing the therapies for Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. phase III include, Genelux Corporation.

Phases

This report covers around 125+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Oncolytic Viruse

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oncolytic Virus Cancer Therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.

Oncolytic Virus Cancer Therapy Report Insights

• Oncolytic Virus Cancer Therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oncolytic Virus Cancer Therapy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Oncolytic Virus Cancer Therapy drugs?
• How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oncolytic Virus Cancer Therapy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genelux Corporation
• Candel Therapeutics
• CG Oncolgy
• DNAtrix
• SillaJen Biotherapeutics
• Oncolytics Biotech
• Wuhan Binhui Biotechnology
• Oryx GmbH
• Jiangsu Sinorda Biomedicine Co., Ltd
• Elicera Therapeutics
• Orgenesis
• Replimune
• Immvira Pharma
• ViroCure
• GeneMedicine
• PsiOxus Therapeutics
• PsiOxus Therapeutics
• Vyriad
• VCN Biosciences
• Beijing Syngentech
• GeneMedicine
• GeneMedicine
• GeneMedicine
• Oncolys BioPharma
• SillaJen Biotherapeutics
• Turnstone Biologics

Key Products

• Olvi-Vec
• CAN-2409
• CG0070
• DNX-2401
• Pexa-Vec
• Pelareorep
• OH 2
• ParvOryx
• SND005
• ELC-100
• AloCelyvir
• RP2
• MVR-C5252
• RC402
• GM 101
• NG-641
• NG-350A
• MV-NIS
• VCN-01
• SynOV 1.3
• GM103
• GM102
• GM104
• OBP-702
• JX-970
• RIVAL-02

This product will be delivered within 1-3 business days.